From the Ionis Pharmaceuticals, Inc. financial results for the three and nine months ended 30 September 2021:

“We are looking forward to multiple near-term catalysts, beginning with the presentation of donidalorsen Phase 2 data in patients with HAE this month. We anticipate initiating the donidalorsen Phase 3 study before year-end”, says Brett P. Monia, Ph.D., CEO of Ionis.
(Source: Ionis)